Chartwell RX LLC

Chartwell RX LLC, a for-profit pharmaceutical manufacturer and distributor based in Congers, New York, supplies branded and generic medications to the Defense Logistics Agency and the Department of Veterans Affairs as a prime contractor delivering through delivery orders under firm fixed-price indefinite delivery vehicles. The company competes full-and-open, with no set-aside designations across its federal footprint.

Chartwell RX's capability portfolio centers on oral pharmaceutical products, particularly ondansetron (an antiemetic medication available in 4 mg and 8 mg formulations), doxycycline hyclate tablets (a broad-spectrum antibiotic), and other critical medications including clarithromycin and linezolid. Representative delivery orders include a $648.6 million firm fixed-price award from the Defense Logistics Agency Medical Supply Chain in February 2026 for "other medical" supplies with completion through April 2027; a $17.1 million delivery order in February 2026 for ondansetron ODT 8 mg tablets (30-count packages); and a $9.1 million delivery order in March 2026 for doxycycline hyclate 100 mg tablets (1,000-count). The company serves as a routine supplier on DLA Troop Support Medical's pharmaceutical catalog, fulfilling rapid-turnaround orders with typical completion windows of one to five days.

Customer concentration is stark. The Defense Logistics Agency Troop Support Medical accounts for 721 of 726 awards (99% by count) but only $10.1 million of combined potential value — a portfolio of hundreds of small delivery orders typically in the $100–$2,000 range. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 anchors the dollar base with a single $449.4 million award, and the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response holds four awards totaling $318.4 million. The divergence between rankings reflects DLA's reliance on Chartwell RX for steady supply of routine medications across multiple small task orders, while VA and HHS awards represent larger contract vehicles with extended performance periods.

Chartwell RX operates under two primary parent vehicles: an indefinite delivery contract (SPE2D020D0005) with 720 task orders carrying $3 million combined potential value, and a multi-million-dollar pharmaceutical procurement vehicle with two task orders valued at $267 million. The vast majority of activity flows through the DLA IDC, generating consistent order volume across calendar years — 105 awards in 2022, 116 in 2023, 175 in 2024, 193 in 2025, and 128 through mid-April 2026. Activity has grown year over year, with 726 total awards and $777.9 million combined potential value since 2020. Of the $777.9 million potential value, $225.4 million (29%) has been obligated, reflecting the payment status of executed orders.

The company holds no sub-awards and reports no subcontractor relationships in the source material. Chartwell RX competes as a standalone prime across its portfolio, with no teaming arrangements disclosed.

Recompete exposure is minimal. Only one award (combined potential value $649 thousand) reaches ultimate completion within the next twenty-four months, indicating that the bulk of Chartwell RX's DLA delivery-order volume has already completed or carries completion dates well beyond mid-2027. The two larger HHS and VA awards, worth $767.8 million combined, do not face recompete within the near term based on the source data.